SYSTEMIC HEMIBODY IRRADIATION
\sɪstˈɛmɪk hˈɛmɪbˌɒdi ˌɪɹe͡ɪdɪˈe͡ɪʃən], \sɪstˈɛmɪk hˈɛmɪbˌɒdi ˌɪɹeɪdɪˈeɪʃən], \s_ɪ_s_t_ˈɛ_m_ɪ_k h_ˈɛ_m_ɪ_b_ˌɒ_d_i_ ˌɪ_ɹ_eɪ_d_ɪ__ˈeɪ_ʃ_ə_n]\
Sort: Oldest first
-
Irradiation of one half or both halves of the body in the treatment of disseminated cancer or widespread metastases. It is used to treat diffuse metastases in one session as opposed to multiple fields over an extended period. The more frequent treatment modalities are upper hemibody irradiation (UHBI) or lower hemibody irradiation (LHBI). Less common is mid-body irradiation (MBI). In the treatment of both halves of the body sequentially, hemibody irradiation permits radiotherapy of the whole body with larger doses of radiation than could be accomplished with WHOLE-BODY IRRADIATION. It is sometimes called "systemic" hemibody irradiation with reference to its use in widespread cancer or metastases. (P. Rubin et al. Cancer, Vol 55, p2210, 1985)
By DataStellar Co., Ltd
Word of the day
Proto Oncogene Proteins c erbB 2
- cell surface protein-tyrosine kinase that is found to be overexpressed in significant number adenocarcinomas. It has extensive homology can heterodimerize EGF EPIDERMAL GROWTH FACTOR), 3 receptor (RECEPTOR, 3) and the 4 receptor. Activation of erbB-2 receptor occurs during heterodimer formation with a ligand-bound erbB family members. EC 2.7.11.-.